Transplantation Immunology.pdf - E-Lib FK UWKS

26 Callaghan and Bradley
101. Kazory, A., and Ducloux, D. (2003). Renal transplantation and polyomavirus
infection: recent clinical facts and controversies. Transplant. Infect. Dis. 5,
65–71.
102. Hirsch, H. H., Knowles, W., Dickenmann, M.,et al. (2002) Prospective study of
polyomavirus type BK replication and nephropathy in renal-transplant recipients.
N. Engl. J. Med. 347, 488–496.
103. Lin, P. L., Vats, A. N., and Green, M. (2001) BK virus infection in renal transplant
recipients. Pediatr. Transplant. 5, 398–405.
104. Foley, R. N., Parfrey, P. .S, and Sarnak, M. J. (1998) Clinical epidemiology of
cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32(5 Suppl.
3), S112–S119.
105. Raine, A. E., Margreiter, R., Brunner, F. P., et al. (1992) Report on management
of renal failure in Europe, 22, 1991. Nephrol. Dial. Transplant. 7(Suppl. 2), 7–
35.
106. Kasiske, B. L., Chakkera, H. A., and Roel, J. (2000) Explained and unexplained
ischemic heart disease risk after renal transplantation. J. Am. Soc. Nephrol. 11,
1735–1743.
107. Foley, R. N. (2003) Clinical epidemiology of cardiac disease in dialysis patients:
left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin.
Dial. 16, 111–117.
108. Holdaas, H., Fellstrom, B., Jardine, A. G., et al.; Assessment of LEscol in Renal
Transplantation (ALERT) Study Investigators (2003) Effect of fluvastatin on
cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled
trial. Lancet 361, 2024–2031.
109. Kwak, B., Mulhaupt, F., Myit, S., and Mach, F. (2000) Statins as a newly recognized
type of immunomodulator. Nat. Med. 6, 1399–1402.
110. Holdaas, H. and Jardine, A. (2003) Acute renal allograft rejections, a role for
statins? Minerva Urol. Nefrol. 55, 111–119.
111. Kasiske, B. L., Vazquez, M. A., Harmon, W. E., et al. (2000) Recommendations
for the outpatient surveillance of renal transplant recipients. American Society
of Transplantation. J. Am. Soc. Nephrol. 11 (Suppl. 15), S1–86.
112. EBPG Expert Group on Renal Transplantation (2002) European best practice
guidelines for renal transplantation. Section IV: long-term management of the
transplant recipient. IV.5.4. Cardiovascular risks. Post-transplant diabetes mellitus.
Nephrol. Dial. Transplant. 17 (Suppl. 4), 28.
113. Ducloux, D., Motte, G., Challier, B., Gibey, R., and Chalopin, J. M. (2000) Serum
total homocysteine and cardiovascular disease occurrence in chronic, stable renal
transplant recipients: a prospective study. J. Am. Soc. Nephrol. 11,134–137.
114. EBPG Expert Group on Renal Transplantation (2002). European best practice
guidelines for renal transplantation. Section IV: Long-term management of the
transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia.
Nephrol. Dial. Transplant. 17 (Suppl. 4), 28.
115. Ducloux, D., Kazory, A., and Chalopin, J. M. (2004) Predicting coronary heart disease
in renal transplant recipients: a prospective study. Kidney Int. 66, 441–447.